# Monopar Therapeutics (MNPR) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Monopar Therapeutics's 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/MNPR/mda/fy2025/): filed 2026-03-27; accession 0001437749-26-010025 (https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/mnpr20251231_10k.htm); latest 10-K
- [FY 2024 MD&A](/company/MNPR/mda/fy2024/): filed 2025-03-31; accession 0001437749-25-009979 (https://www.sec.gov/Archives/edgar/data/1645469/000143774925009979/mnpr20241231_10k.htm)
- [FY 2023 MD&A](/company/MNPR/mda/fy2023/): filed 2024-03-28; accession 0001437749-24-009687 (https://www.sec.gov/Archives/edgar/data/1645469/000143774924009687/mnpr20231231_10k.htm)
- [FY 2022 MD&A](/company/MNPR/mda/fy2022/): filed 2023-03-23; accession 0001654954-23-003384 (https://www.sec.gov/Archives/edgar/data/1645469/000165495423003384/mnpr_10k.htm)
- [FY 2021 MD&A](/company/MNPR/mda/fy2021/): filed 2022-03-24; accession 0001654954-22-003701 (https://www.sec.gov/Archives/edgar/data/1645469/000165495422003701/mnpr_10k.htm)

Back to /company/MNPR/